DERACYN IN THE TREATMENT OF SOCIAL PHOBIA--PILOT STUDY IN OUTPATIENTS

DERACYN 治疗社交恐惧症——门诊患者试点研究

• 批准号: 3739968
• 负责人: ROBERT N. GOLDEN
• 金额: --
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3739968
• 关键词: antidepressants; drug screening /evaluation; human subject; human therapy evaluation; mental disorder chemotherapy; phobias; social behavior

This is a study designed to evaluate the efficacy of adinazolam (Deracyn) vs. placebo in outpatients with social phobia and the safety profile of adinazolam in this patient population. If safety and effective, the pilot data will be used to determine the effective size of active treatment in planning for a multicenter trial. A second objective is the determination of 3H-paroxetine binding sites, a measure of serotonin function, at baseline and at the end of treatment.

本研究旨在评价阿地那唑仑（Deracyn）的疗效 与安慰剂相比，在社交恐惧症门诊患者中的安全性特征 阿地那唑仑在该患者人群中的应用。 如果安全有效， 试验数据将被用来确定有效的大小， 多中心试验计划中的治疗。 第二个目标是 测定3 H-帕罗西汀结合位点，测定血清素 功能，在基线和治疗结束。